D-1002-2020 Class III Terminated

Recalled by The Harvard Drug Group — Livonia, MI

FDA drug recall D-1002-2020 was initiated by The Harvard Drug Group on Feb 27, 2020 and is designated Class III. Reason for recall: Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets. The recall status is terminated (terminated Sep 24, 2022).

Recall details

Product Type
Drugs
Report Date
Mar 18, 2020
Initiation Date
Feb 27, 2020
Termination Date
Sep 24, 2022
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Quetiapine Fumarate Extended-Release Tablets, 300 mg, 100 tablets per unit dose carton, Rx only, Manufactured by: Lupin Limited, Pithampur (M.P.) 454775 India; Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152 USA. NDC: 0904-6804-61

Reason for recall

Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

Distribution pattern

Nationwide

Code information

Lot, expiry: Lot N00037, exp 05/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1002-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1002-2020. Report a data issue: hello@regdatalab.com.